34
Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB- Pharma, a pharmaceutical company that sells anti- inflammatory drugs (one of the five approved TNF blockers) and anti-histamines. Additional immunology-related therapeutics are in late phase clinical testing -My wife and I own stock in several biotechnology companies that make anti-inflammatory drugs and/or are currently in late phases of testing such drugs Management of conflicts of interest -I will not comment on relative advantages or disadvantages of specific products or potential products made by these companies vs. competitive products of other companies

Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Embed Size (px)

Citation preview

Page 1: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Conflict of Interest StatementAnthony DeFranco

Identified conflicts of interest-I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical company that sells anti-inflammatory drugs (one of the five approved TNF blockers) and anti-histamines. Additional immunology-related therapeutics are in late phase clinical testing-My wife and I own stock in several biotechnology companies that make anti-inflammatory drugs and/or are currently in late phases of testing such drugs

Management of conflicts of interest-I will not comment on relative advantages or disadvantages of specific products or potential products made by these companies vs. competitive products of other companies

Page 2: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation and Innate Immunity (part I)

• Inflammation• Innate immunity and the initial response to

infection• Cytokines that induce inflammation and

direct inflammatory cells• Recognition of microbes by Toll-like

receptors (TLRs) and other innate recognition elements

• Inflammation and recruitment of phagocytes• Uptake and killing of bacteria by phagocytes• Innate immunity against fungi, helminths, at

mucosal epithelium

Page 3: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Source: Wikipedia

QuickTime™ and a decompressor

are needed to see this picture.

Inflammation

Page 4: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation

“rubor et tumor cum calore et dolore”

(redness and swelling with heat and pain)

--Cornelius Celsus in De Medicina, 1st century A.D.

later “functio laesa” (disturbance of function) was added

Page 5: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation

“rubor et tumor cum calore et dolore”

(redness and swelling with heat and pain)

--Cornelius Celsus in De Medicina, 1st century A.D.

later “functio laesa” (disturbance of function) was added

Inflammation is an adaptive response to noxious conditions (infection and tissue injury)--an attempt to restore homeostasis

Page 6: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation

• Inflammation can be induced by immune recognition of infection or tissue damage (usually good)

• Inflammation can be induced by immune recognition that is hypersensitive to environmental components or autoinflammatory or autoimmune (=disease)

Page 7: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation

• Inflammation can be induced by immune recognition of infection or tissue damage (usually good)

• Inflammation can be induced by immune recognition that is hypersensitive to environmental components or autoinflammatory or autoimmune (=disease)

• Acute inflammation: influx of white blood cells and fluid from blood to fight infection and aid tissue repair

• Chronic inflammation: inducer of inflammation is not removed– Leads to tissue damage and loss of tissue function (joint

destruction, lung fibrosis, etc.)– Current view: aggressively fight inflammation in certain

chronic diseases to decrease/delay progressive loss of function

Page 8: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation

• Inflammation can be induced by immune recognition of infection or tissue damage (usually good)

• Inflammation can be induced by immune recognition that is hypersensitive to environmental components or autoinflammatory or autoimmune (=disease)

• Acute inflammation: influx of white blood cells and fluid from blood to fight infection and aid tissue repair

• Chronic inflammation: inducer of inflammation is not removed– Leads to tissue damage and loss of tissue function (joint

destruction, lung fibrosis, etc.)– Current view: aggressively fight inflammation in certain chronic

diseases to decrease/delay progressive loss of function• Current research suggests that inflammation may play an important

role in common chronic diseases including atherosclerosis, type 2 diabetes, neurodegeneration, and cancer

Page 9: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Immune sentinel cells in the tissues: dendritic cells

Langerhans cells (epidermal dendritic cells) in the skinWJ Mullholland et al. J. Invest. Dermatol. 126: 1541, 2006.

QuickTime™ and a decompressor

are needed to see this picture.

Green= dendritic cellsBlue= nuclei of all cells

Page 10: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Infection leads to production of inducers of inflammation

TNF

or dendritic cell

Inflammatory mediators:Complex and many, but include:Lipids andProteins (cytokines/chemokines)

Others

QuickTime™ and a decompressor

are needed to see this picture.

Page 11: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Cytokines• “Cytokines” are soluble protein mediators secreted by

immune cells (mostly) that act on other cells to regulate their activity; many are called “interleukins” (IL-1, IL-2, etc.) (note: sometimes exist in cell-bound forms)

• Cytokines have many functions, we’ll focus on a few central functions of some key cytokines (see “Cytokine primer” in syllabus)

• Name of a cytokine often doesn’t reflect its most important function (example: TNF stands for “tumor necrosis factor” but main function is to induce inflammation)

• A subfamily of cytokines primarily functions in directing migration of cells, these are called “chemotactic cytokines” or “chemokines”

Chemokines have systematic names: CCL1, 2, … and CXCL1, 2, …(but older names sometimes used, including IL-8)

Page 12: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

The Initial Response to Infection: Innate Immunity

• Recognition of types of molecules (“molecular patterns”) made by microbes or viruses but not by our cells by innate immune receptors

• Alternatively, recognition of tissue damage and cell death, which are often associated with infection (“danger”).

• Rapid mobilization of leukocytes to the site of infection or damage and influx of plasma into the tissue site (=inflammation)

• Recruited innate immune cells kill microbes or virally infected cells. Immune cells also can promote tissue repair but when dysregulated can exacerbate tissue injury

• Also, innate recognition promotes the adaptive immune response, which is slower but more powerful

Page 13: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Cytokines and Inflammation

• Macrophages or DCs stimulated via innate immune receptors make pro-inflammatory cytokines, especially TNF (Tumor necrosis factor), IL-1, and IL-6

• TNF and IL-1 signal to endothelial cells to make them:– Leaky to fluid (influx of plasma; containing

antibodies, complement components, etc.)– Sticky for leukocytes, leading to influx of first

neutrophils, later monocytes, lymphocytes• IL-6 promotes adaptive immune responses and has

systemic effects (“acute phase response” of liver, including C-reactive protein or CRP; levels used clinically as an indication of systemic inflammation)

Page 14: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Leukocyte recruitment to sites of inflammation

See Abbas and Lichtman Fig. 2-7

or DCQuickTime™ and a

decompressorare needed to see this picture.

Note: molecular details of leukocyte extravasation will be covered in lecture Thursday

Page 15: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation: Neutrophils vs. Monocytes

• Acute inflammation is initially characterized as rich in neutrophils; later it is more monocytes and lymphocytes. This is controlled by which chemokines are expressed by the endothelial cells.

• Neutrophils are dedicated to killing microbes and are short-lived. They often damage host tissue as a byproduct.

• Monocytes are multi-potential, depending on cytokine signals:

+IFN-g: assume a vigorous killing phenotype similar to neutrophils

+IL-4: “alternatively activated macrophages”; tissue repair, barrier immunity

+IL-10: assume a wound-healing type phenotype (to clean up after infection is cleared)

Page 16: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Anti-Inflammatory Therapeutics

• NSAIDs: inhibitors of inflammation and fever (block prostaglandin synthesis)

• Glucocorticoids are also potent anti-inflammatory drugs; natural systemic anti-inflammatory mechanism

• Agents that block TNF are effective in treating rheumatoid arthritis, Crohn’s disease, etc.

• Agents that block IL-1 are less effective for these diseases but are useful for some genetic inflammatory diseases

Page 17: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

How is infection first recognized by the immune system?

• What is seen by innate immunity?– Types of molecules made by microbes, but not by our cells

“Pathogen-associated molecular patterns” PAMPs– Molecules released from necrotic cells, tissue damage

(“damage-associated molecular patterns” DAMPs). (Note: tissue damage can also be recognized by pain neurons, which can promote inflammation)

• What mediates the recognition?– Diverse recognition elements; 4 key families of cellular

receptors:• Toll-like receptors (TLRs)• C-type lectin receptors (CLRs)• RigI-like receptors (RLRs)• NOD-like receptors (NLRs)

Page 18: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Innate recognition outside the cell or in endosomes:TLRs and CLRs

Modified from Abbas and Lichtman Fig. 2-2

CLRs detect mostly carbohydrates (fungi especially); also recognize dead host cells; induce cytokines

TLRs induce inflammatory cytokines (+ interferon)

Endosomal TLRs recognize nucleic acids (mostly from virus particles). Localization in endosomes is thought to aid discrimination between virus-derived and endogenous nucleic acids

Surface CLRscarbohydrates

TLR4 recognizes LPS

Page 19: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Sepsis Syndrome: very bad(too much of a good thing)

• Bacterial septicemia leads to activation of TLRs on monocytes in the blood, DCs in spleen

• Systemic release of TNF and IL-1 leads to “inflammation” all over the body

• Shock from loss of blood pressure (vasodilation and leakage of fluid into tissues)

• TLRs also induce coagulation (via tissue factor)– Current therapy with some efficacy: “activated protein

C”: promotes fibrinolysis, breaks down thrombi• The combination of effects frequently leads to

multi-organ failure and death

Page 20: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Innate recognition in the cytoplasm:NLRs and RLRs

Modified from Abbas and Lichtman Fig. 2-2

Inflammatory cytokines

Engulfment of bacteria invading the cytoplasm (autophagy)

Secrete anti-microbial peptides into lumen of crypts of sm. intest.

(RLRs)

Peptidoglycan

Page 21: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Common alleles of NOD2 are a genetic risk factor for Crohn’s

disease

• Several moderately common alleles of the NOD2 gene (7% of total alleles) increase susceptibility to Crohn’s disease (a form of inflammatory bowel disease)

• Two copies of these alleles increase susceptibility by 40X

• Mechanism: most evidence indicates these are loss-of-function alleles; unknown which function of NOD2 is most relevant

Page 22: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Processing of IL-1 and related cytokines: an important regulatory

step• Some “NLRs” assemble to form the “inflammasome” which

proteolytically processes IL-1 and related cytokines (IL-18) to their active, secreted forms.

• Inflammasome in activated by cellular stress or recognition of microbial components in the cytoplasm

Page 23: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Processing of IL-1 and related cytokines: an important regulatory

step• Some “NLRs” assemble to form the “inflammasome” which

proteolytically processes IL-1 and related cytokines (IL-18) to their active, secreted forms.

• Inflammasome in activated by cellular stress or recognition of microbial components in the cytoplasm

• Genetic periodic fever syndromes are due to activating mutations in the inflammasome (active when it shouldn’t be)

• Inflammasome is activated by some types of small crystals that can be phagocytosed by macrophages, important role in Gout

Page 24: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

The Inflammasome activates caspase 1 in response to cellular

insults

QuickTime™ and a decompressor

are needed to see this picture.

Phagocytosed crystalsBacterial pore-forming toxinsEfflux of K+

Bacterial flagellinOther insults/stresses

Several different NLRs can form inflammasomes (shown is NLRP3/NALP3)

QuickTime™ and a decompressor

are needed to see this picture.

Page 25: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inducers of Inflammation

• Microbe PAMPs recognized by TLRs, NOD1/2 or CLRs: DCs, macrophages makeTNF and IL-1

• Virus infections: infected cells, pDCs make IFN/ (type 1)• Tissue damage (cell necrosis etc.): “DAMPs” activate DCs,

macrophages via TLRs, CLRs, inflammasomes (other receptors?)

• Complement fragments (innate activators or IgM or IgG + antigen)

• Mast cell activation (IgE+allergen or innate mechanisms: release histamine, leukotrienes, cytokines): eosinophil-rich inflammation (“type 2 immunity”)

• Effector T cells responding to antigen (TNF + other cytokines; chemokines)

Page 26: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Negative Regulation of Inflammation

• Cells responding to innate stimuli stop making inflammatory mediators after short time period and convert to making anti-inflammatory lipids (resolvins, etc.) and anti-inflammatory cytokines (IL-10, TGF-)

• Killing the infectious agent and removal of the dead cells, debris, crystals, etc. will stop stimulation of incoming inflammatory cells

• Systemic elevation of inflammatory cytokines (esp. IL-1) in severe infections induce production of glucocorticoids, which are anti-inflammatory (also increased by stress)

• Regulatory T cells are also anti-inflammatory, both by blocking effector T cells and by inhibiting innate cells

Page 27: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Phagocytosis and Killing of Microbes

Abbas and Lichtman Fig. 2-9

Page 28: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Phagocytosis and Killing of Microbes

Abbas and Lichtman Fig. 2-9

Key Concepts related to phagocytosis:

1. Opsonization: soluble immune recognition elements tag a particle for phagocytosis (opsonins include: Mannose-binding lectin, C3b, IgG, etc.)

2. Interferon- from NK cell or Th1 cell promotes killing of internalized microbes by monocytes/macrophages

3. Killing mechanisms: ROI, NO, proteases, anti-microbial peptides

Page 29: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Phagocytosis and Killing of Microbes

Abbas and Lichtman Fig. 2-9

Genetic defects in phagocyte oxidase components: “chronic granulomatous disease”

Key Concepts related to phagocytosis:

1. Opsonization: soluble immune recognition elements tag a particle for phagocytosis (opsonins include: Mannose-binding lectin, C3b, IgG, etc.)

2. Interferon- from NK cell or Th1 cell promotes killing of internalized microbes by monocytes/macrophages

3. Killing mechanisms: ROI, NO, proteases, anti-microbial peptides

Page 30: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Innate Immunity against fungal pathogens

• CLRs are key innate recognition elements for fungi/yeast (TLRs can also play a role)

• Neutrophils are important for killing most fungal pathogens

• Some fungal pathogens can establish intracellular infections (like some bacterial pathogens): interferon- is important for defense; often also NO

Page 31: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Innate Immunity against helminths

• Often multicellular parasites induce a “type 2” inflammation characterized by influx of eosinophils and basophils instead of neutrophils and monocytes

• This type of inflammation is also seen in asthma and allergies, as will be discussed later in the course and can be propagated by Th2 adaptive immunity and/or IgE

• Innate recognition is not yet understood, may include foreign polysaccharides (chitin), proteases, tissue damage

• In some parasitic worm infections inside tissue, bacteria in the gut/feces of the worm stimulate TLRs and neutrophil-rich inflammation, which can cause pathology (African river blindness)

Page 32: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Innate Immunity and Mucosal Epithelium

• Microbes are tolerated outside mucosal epithelium when consistent with its function (colon; upper airways)

• Efforts to keep microbes out of some mucosal epithelial regions (small intestines and small airways)

• Mechanisms include: actions of some surfactant proteins in lungs (bind to foreign polysaccharides); secretion of anti-microbial peptides by Paneth cells in crypts of small intestines; secretion of mucus by goblet cells; T cells in epithelial tissue; IgA

• IL-13 is an important cytokine promoting mucus secretion

Page 33: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Tomorrow: Innate Immunity to Viruses

Page 34: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

REMINDER:The 1PM session is a live patient

interview session, so be here promptly by 1:10 and no electronics or eating food

when patient is on stage

Patient Confidentiality must be maintained